2023 was a tricky yr to the biopharma sector, with a number of providers downsizing and restructuring their workforces to remain afloat. You can find signs of recovery, as mergers and acquisitions picked up over the pharmaceutical and existence sciences field within the latter Portion of 2023 and have ongoing https://sites.google.com/view/bio-sites/blog